Primary source: Open Government Licence v3.0
Translated From French
PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.
A set of 14 Field Safety Notices (FSNs) was issued on 3 September 2026, mandating healthcare professionals to act upon safety alerts for specific medical devices.
The field safety notices identify potential risks associated with medical devices, ensuring that healthcare professionals are alerted to take necessary actions to mitigate patient safety concerns.
Healthcare professionals must act on the issued FSNs as outlined by MHRA, ensuring compliance to address any safety concerns associated with the listed medical devices.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Healthcare professionals must act on the issued FSNs as outlined by MHRA, ensuring compliance to address any safety concerns associated with the listed medical devices.
The Medicines and Healthcare products Regulatory Agency (MHRA) issued a series of Field Safety Notices (FSNs) between 24 to 28 August 2026, which inform healthcare professionals of safety issues related to various medical devices and require mandatory action. The FSNs include notable products such as Aesculap's Metha CoCr modular neck system, Bausch & Lomb's EyeFill C, and Medtronic's Newport HT70 Ventilator, among others.
What changed: A set of 14 Field Safety Notices (FSNs) was issued on 3 September 2026, mandating healthcare professionals to act upon safety alerts for specific medical devices.
Why it matters: The field safety notices identify potential risks associated with medical devices, ensuring that healthcare professionals are alerted to take necessary actions to mitigate patient safety concerns.
Practical implication: Healthcare professionals must act on the issued FSNs as outlined by MHRA, ensuring compliance to address any safety concerns associated with the listed medical devices.
Published from the regulator source ingestion pipeline after PV impact triage.
Monitor the supply chain developments and prepare to adjust inventory management practices as the end of the shortage approaches.
Monitor for changes in labeling requirements and risk management strategies as a result of the ongoing review by PRAC.
Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.
Regulatory compliance workflows involving the Dengue Tetravalent Vaccine outside the EU need to incorporate the EMA's positive opinion concerning its use in individuals aged 4 to 60.
